ERBB2 and breast cancer: As shown in Additional file 2: Table S2, among HER2+ and TN residual breast cancers, the take rate was found univariately to be greater in residual tumors with Ki-67 > 14% than the residual tumors with Ki-67 ≤ 14% (p = 0.0280) and somewhat greater in TN disease than HER2-enriched disease (p = 0.0882).